百奥赛图-B2024 中期报告

百奧賽圖北京醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司） Stock code股份代號：2315 INTERIM REPORT中 期 報 告2024 CONTENTS 2Corporate Information6Financial Summary7Management Discussion and Analysis59Corporate Governance and Other Information84Review Report86Consolidated Statements of Profit or Loss and OtherComprehensive Income87Consolidated Statements of Financial Position89Consolidated Statements of Changes in Equity91Condensed Consolidated Cash Flow Statements92Notes to the Unaudited Interim Financial Report118Definition Corporate Information CHINESE NAME()ENGLISH NAMEBiocytogen Pharmaceuticals (Beijing) Co., Ltd.* BiocytogenPharmaceuticals(Beijing)Co., Ltd.* 02315 STOCK CODE02315 LEGAL REPRESENTATIVEDr. Shen Yuelei CHAIRMAN OF THE BOARDDr. Shen Yuelei HEADOFFICES AND PRINCIPLE PLACE OFBUSINESS IN CHINA 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC REGISTERED OFFICE 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC PRINCIPALPLACE OF BUSINESS IN HONGKONG 24840 40th Floor, Dah Sing Financial CenterNo. 248 Queen’s Road EastWanchaiHong Kong * *For identification purposes only. Corporate Information BOARD OF DIRECTORS Executive Directors Dr. Shen Yuelei(Chairman, Chief Executive Officer and General Manager)Dr. Ni JianDr. Zhang Haichao(Senior Operation Director of Animal Center) Non-executive Directors Mr. Wei YiliangDr. Zhou KexiangMs. Zhang Leidi Independent Non-executive Directors Mr. Hua FengmaoDr. Yu ChangyuanMs. Liang Xiaoyan SUPERVISORS Ms. Li YanMs. Sun ChunliDr. Yao Jiawei AUDIT COMMITTEE Ms. Liang Xiaoyan(Chairman)Mr. Hua FengmaoDr. Yu ChangyuanMr. Wei Yiliang REMUNERATION AND EVALUATION COMMITTEE Mr. Hua Fengmao(Chairman)Ms. Liang XiaoyanDr. Yu ChangyuanDr. Ni Jian Corporate Information NOMINATION COMMITTEE Dr. Yu Changyuan(Chairman)Mr. Hua FengmaoMs. Liang XiaoyanDr. Shen Yuelei STRATEGY DEVELOPMENT COMMITTEE Dr. Shen Yuelei(Chairman)Dr. Zhou KexiangMr. Wei YiliangMs. Zhang Leidi JOINT COMPANY SECRETARIES Mr. Wang YongliangMs. Au Wai Ching(associate member of The Hong Kong CharteredGovernance Institute and The Chartered Governance Institute inthe United Kingdom) AUTHORIZED REPRESENTATIVES Dr. Shen YueleiMs. Au Wai Ching AUDITOR 108 KPMGCertified Public Accountants(Public Interest Entity Auditor registered in accordance with theAccounting and Financial Reporting Council Ordinance)8th Floor, Prince’s Building10 Chater RoadCentral, Hong Kong Corporate Information H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong LEGAL ADVISERS TO HONG KONG LAW 3A10 Davis Polk & Wardwell10th Floor, The Hong Kong Club Building3A Chater Road, Hong Kong PRINCIPAL BANKS 2 ChinaConstruction Bank Beijing Economic and TechnologicalDevelopment Zone Sub-branchNo. 2, Jingyuan North StreetDaxing DistrictBeijing, PRC 881 China Merchants Bank, Beijing Yizhuang Sub-branch1/F, Building 8, Libao PlazaNo. 8 Ronghua Middle RoadDaxing DistrictBeijing, PRC COMPANY WEBSITE http://www.biocytogen.com.cn http://www.biocytogen.com.cn CONTACT INFORMATION FOR INVESTORS Tel.: 010-56967601Fax: 010-56967666-8067Email: ir@bbctg.com.cn Tel.: 010-56967601Fax: 010-56967666-8067Email: ir@bbctg.com.cn Management Discussion and Analysis I. I.BUSINESS REVIEW Overview 2 0 0 9RenMice®RenBiologicsTM1,00040BioMice® Founded in 2009, we are a global biotechnology company thatdrivesthe research and development of novel antibodybaseddrugswith innovative technologies.Founded on gene editingtechnology,we leverage genetically engineered proprietaryRenMice®platforms for fully human antibody discovery,andhas established a sub-brand, RenBiologicsTM, to explore globalpartnershipsfor an off-the-shelf library of more than 400,000fullyhuman antibody sequences against approximately 1,000targetsfor worldwide collaboration.Biocytogen also reachedseveralantibody molecules in clinical stage out-licensing orcollaboration, and currently provides a few thousand off-the-shelfanimaland cell models under the Company’s sub-brand,BioMiceTM, along with preclinical pharmacology and gene-editingservicesfor clients worldwide.Biocytogen headquartered inBeijing and has branches in China (Haimen Jiangsu, Shanghai),USA (Boston, San Francisco), and Germany (Heidelberg). 2024202320242 0 2 42024 In 2024, there exist significant uncertainties in the internationalpolitics and the global economy, which in particular caused majorshocksto the biopharmaceutical industry in China.Althoughtheinternal and external environments have brought us manychallenges, leveraging our forward-looking strategic layout andtimely internal adjustments in 2023, our results in the first halfof 2024 maintained a good growth momentum. While operatingincome grew rapidly, there recorded a dramatic narrowi